On Friday, Shares of Mylan NV (NASDAQ:MYL), gained 1.33% to $48.05.
Mylan N.V., declared that the U.S. Patent and Trademark Office (PTO) has instituted an inter partes review (IPR) proceeding on all claims against a third Copaxone 40 mg/mL patent, U.S. Patent No. 8,969,302, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The patent relates to methods for the treatment of multiple sclerosis through the administration of at least three 40 mg/mL subcutaneous injections of glatiramer acetate per week.
On Aug. 25, 2015, Mylan declared that the PTO instituted IPR proceedings against two related Copaxone 40 mg/mL patents, U.S. Patent Nos. 8,232,250 and 8,399,413, on all claims. The oral hearing for all three IPRs has been planned for May 12, 2016.
In August 2014, the U.S. Food and Drug Administration accepted Mylan’s abbreviated new drug application (ANDA) filing for a three times per week Glatiramer Acetate Injection 40 mg/mL, the generic version of Copaxone 40 mg/mL Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and anticipates to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Shares of Centurylink Inc (NYSE:CTL), declined -2.15% to $26.19, during its last trading session.
CenturyLink, declared that its Board of Directors voted to declare a regular quarterly cash dividend of $0.54 per share, a portion of which will be payable out of capital surplus, on September 22, 2015, to shareholders of record on September 8, 2015.
CenturyLink, Inc. provides various communications services to residential, business, governmental, and wholesale customers in the United States. It operates through two segments, Business and Consumer.
Finally, Fiat Chrysler Automobiles NV (NYSE:FCAU), ended its last trade with -1.95% loss, and closed at $ 13.60.
Fiat Chrysler Automobiles, North America Vice President of Manufacturing Brian Harlow, joined by the Company’s Vice President of Transmission Powertrain Jeffrey Lux, acknowledged the achievement during employee events recently at both the Indiana Transmission Plant I (ITPI) and the Tipton Transmission Plant, where the nine-speed has been built since May 2013.
“Five years ago, when Chrysler Group declared that it would build the nine-speed automatic transmission in Indiana, it was a huge vote of confidence in the skills, knowledge and expertise of our local workforce, especially because ITPI would be the first plant ever to build the nine-speed,” said Harlow. “This was a noteworthychallenge, but an even greater opportunity. There was a lot riding on our employees’ ability to deliver.
“Recently, as we celebrate the one millionth nine-speed produced, I can honestly say that everyone involved rose to the challenge and exceeded expectations,” Harlow continued. “You have proven that our decision to invest here was a wise one and demonstrated what makes this workforce one of the best in the business.”
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
